171 542

Cited 12 times in

Prognostic significance of systemic inflammatory response in stage II colorectal cancer

Oh, SY  | Kim, YB  | Suh, KW
The Journal of surgical research, 208. : 158-165, 2017
Journal Title
The Journal of surgical research
BACKGROUND: It is considered that stage II colorectal cancers have heterogeneous oncological outcomes. It remains to be determined whether inflammatory markers can predict survival after curative surgery in these patients. The aim of this study was to investigate the prognostic impact of preoperative inflammatory markers after curative surgery in stage II colorectal cancers.
METHODS: Two hundred sixty-one patients with stage II colorectal cancers who underwent curative surgery between January 2006 and December 2011 were reviewed. Oncologic outcomes were analyzed with neutrophil count, lymphocyte count, monocyte count, neutrophil to lymphocyte ratio (NLR), and lymphocyte to monocyte ratio.
RESULTS: Univariate analysis showed that high NLR (hazard ratio (HR), 3.506: 95% confidence interval [CI], 1.415-8.688: P = 0.007) and low LMR (HR, 2.436: 95% CI, 1.010-5.880: P = 0.048) were associated with worse disease-free survival (DFS), and high NLR (HR, 2.834: 95% CI, 1.419-5.662: P = 0.003) and low LMR (HR, 2.374: 95% CI, 1.188-4.742: P = 0.014) were associated with worse overall survival (OS) in stage II colorectal cancer. Cox multivariate analysis demonstrated that high NLR was independently associated with worse DFS (HR, 3.163: 95% CI, 1.058-9.455: P = 0.004) and OS (HR, 3.018: 95% CI, 1.467-6.207: P = 0.003) in stage II colorectal cancer.
CONCLUSION: Among the systemic inflammatory markers, NLR is a strong predictor of worse DFS and OS in stage II colorectal cancer.

Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Ajou Authors
김, 영배  |  서, 광욱  |  오, 승엽
Files in This Item:


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.